PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Breast Cancer Res Treat. Author manuscript; available in PMC Sep 1, 2012.
Published in final edited form as:
PMCID: PMC3355661
NIHMSID: NIHMS360721
Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes
Sarah J. Nyante, Marilie D. Gammon, Jay S. Kaufman, Jeannette T. Bensen, Dan Yu Lin, Jill S. Barnholtz-Sloan, Yijuan Hu, Qianchuan He, Jingchun Luo, and Robert C. Millikan
Sarah J. Nyante, Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA;
sarah.nyante/at/nih.gov
Adipocytokines are produced by visceral fat, and levels may be associated with breast cancer risk. We investigated whether single nucleotide polymorphisms (SNPs) in adipocytokine genes adiponectin (ADIPOQ), leptin (LEP), and the leptin receptor (LEPR) were associated with basal-like or luminal A breast cancer subtypes. 104 candidate and tag SNPs were genotyped in 1776 of 2022 controls and 1972 (200 basal-like, 679 luminal A) of 2311 cases from the Carolina Breast Cancer Study (CBCS), a population-based case–control study of whites and African Americans. Breast cancer molecular subtypes were determined by immunohistochemistry. Genotype odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. Haplotype ORs and 95% CIs were estimated using Hapstat. Interactions with waist-hip ratio were evaluated using a multiplicative interaction term. Ancestry was estimated from 144 ancestry informative markers (AIMs), and included in models to control for population stratification. Candidate SNPs LEPR K109R (rs1137100) and LEPR Q223R (rs1137101) were positively associated with luminal A breast cancer, whereas ADIPOQ +45 T/G (rs2241766), ADIPOQ +276 G/T (rs1501299), and LEPR K656N (rs8129183) were not associated with either subtype. Few patterns were observed among tag SNPs, with the exception of 3 LEPR SNPs (rs17412175, rs9436746, and rs9436748) that were in moderate LD and inversely associated with basal-like breast cancer. However, no SNP associations were statistically significant after adjustment for multiple comparisons. Haplotypes in LEP and LEPR were associated with both basal-like and luminal A subtypes. There was no evidence of interaction with waist-hip ratio. Data suggest associations between LEPR candidate SNPs and luminal A breast cancer in the CBCS and LEPR intron 2 tag SNPs and basal-like breast cancer. Replication in additional studies where breast cancer subtypes have been defined is necessary to confirm these potential associations.
Keywords: Adiponectin, Leptin, Leptin receptor, Breast cancer, Subtypes, Single nucleotide polymorphism
Much of the interest in the basal-like subtype of breast cancer is due to its association with tumor characteristics associated with poor prognosis, higher prevalence in younger and African American women, higher prevalence among BRCA1 carriers, and poorer survival when compared with breast cancers expressing the estrogen receptor (ER) [19]; however, the etiology of this tumor subtype remains largely unknown. The Carolina Breast Cancer Study (CBCS) previously reported that basal-like breast cancer was associated with elevated waist-hip ratio (WHR) [10]. One potential mechanism that may explain this association is the induction of pro-tumor pathways by adipocytokines [11, 12]. Adipocytokines are hormones produced in visceral adipose tissue, and circulating levels are correlated with obesity [1113]. Adipocytokines are also expressed in breast tissue, and have been shown to affect cell proliferation, migration, and invasion [11, 12,14]. Lower circulating levels of one particular adipocytokine, adiponectin, have been associated with breast cancer in some studies [1519], though others have reported no association [20]. Case–control studies of the association between circulating levels of another adipocytokine, leptin, and breast cancer have been inconclusive, whereas a prospective study of leptin and breast cancer risk was null [17, 2124].
Studies of the association between single nucleotide polymorphisms (SNPs) in the adiponectin (ADIPOQ), leptin (LEP), and leptin receptor (LEPR) genes and breast cancer risk have shown little consistency [21, 2530]. For example, LEPR Q223R is the most commonly studied SNP in these genes, and has been reported as positively, inversely, and not associated with breast cancer [21, 25, 2730]. It is possible that some of the variation in reported ADIPOQ, LEP, and LEPR SNP associations is due to tumor heterogeneity, and that stratification by tumor subtype will reveal subtype-specific associations, as has been demonstrated by others [10, 3134].
Therefore, we investigated the association between SNPs in ADIPOQ, LEP, and LEPR and basal-like breast cancer, luminal A breast cancer, and breast cancer overall (all cases compared to controls). The relationship between adipocytokines and visceral fat led us to also evaluate interaction between SNPs and WHR, a proxy for central obesity. This analysis focused on basal-like breast cancer due to the specific nature of our hypothesis that basal-like breast cancer risk may be influenced by adipocytokines. Luminal A breast cancer was the most common breast cancer subtype in the CBCS and shows traditional associations with breast cancer risk factors [5, 10]; it is included in this analysis as a point of reference.
Study population
The CBCS is a population-based case–control study of breast cancer in North Carolina, and has been described previously [10, 35, 36]. Eligible cases were women aged 20–74, diagnosed with primary invasive breast cancer from 1993 to 2001, and living within the study area. Randomized recruitment was used to oversample African American cases and cases younger than 50-years old [37]. Eligible women diagnosed with breast carcinoma in situ were also enrolled from 1996 to 2001. Women aged 20 to 74 years, residing within the study area, and without a history of breast cancer were eligible controls, and were frequency-matched to cases by race and age.
Participants provided informed consent and completed an in-home interview about social and demographic characteristics, medical history, and potential breast cancer risk factors. Height, weight, waist circumference, and hip circumference were measured by a trained nurse. Participants were also asked to provide a blood sample. DNA was extracted from blood and stored at −80°C. A total of 2311 cases and 2022 controls were enrolled. 2045 (88%) cases and 1818 (90%) controls provided a blood sample, and 2039 (88%) cases and 1818 (90%) controls had DNA available for genotyping.
Cases provided written consent for access to medical records and formalin-fixed paraffin-embedded tumor tissue blocks. Immunohistochemistry staining and scoring procedures for the ER, progesterone receptor (PR), human epidermal growth factor receptors 1 and 2 (EGFR and HER2), and cytokeratin (CK) 5/6 have been described in detail by others [5, 10, 38, 39]. Tumor tissue was available for 1845 of 2311 (80%) cases, and immunohistochemistry was completed for 1424 of 2311 (62%) cases. Tumors were classified as follows: 225 basal-like (ER−, PR−, HER2−, CK 5/6+ and/or EGFR+), 796 luminal A (ER+ and/or PR+, HER2−), 137 luminal B (ER+ and/or PR+, HER2+), 116 HER2+/ER− (ER−, PR−, HER2+), and 150 unclassified (ER−, PR−, HER2−, CK 5/6−, and EGFR−) [5, 39, 40]. Cases with missing subtype data were more likely to be non-African American and to have an earlier stage at diagnosis [10].
SNP selection
SNPs were selected using pairwise tagging in Tagger (r2 ≥ 0.80) [41, 42]. The majority of CBCS participants were white or African American, so SNPs were selected from the International HapMap Project CEU and YRI populations; ASW genotypes were unavailable at the time of SNP selection [43]. Tag selection was performed separately in CEU and YRI data for SNPs with a minimum minor allele frequency (MAF) of 0.10, combined into a single list, and genotyped in all participants. Pairwise tagging for LEPR required more than 90 SNPs; tagging was repeated using aggressive tagging, which reduced the number of SNPs by 15 [41]. The list of tag SNPs was supplemented by “candidate” SNPs—SNPs with a reported in vitro functional effect or that had been investigated for an association with breast cancer risk (MAF ≥ 0.05).
158 ancestry informative markers (AIMs) were also genotyped to estimate African and European ancestry [44]. AIMs were selected from a panel that has been used previously by others to estimate ancestry in African Americans, and maximized Fisher’s information content and the difference in allele frequencies between ancestral populations [45, 46].
Genotyping results and quality control
SNPs were genotyped as part of a larger set of 1536 SNPs by the UNC Mammalian Genotyping Core using the Illumina GoldenGate assay (Illumina, Inc, San Diego, CA). Assay intensity data and genotype cluster images for all SNPs were reviewed individually. 163 SNPs were excluded due to low signal intensity or inability to distinguish between genotype clusters. Blind duplicates of 169 samples were genotyped to verify the reproducibility of genotype calls. Concordance between duplicates was greater than 99.8% for all pairs.
Exact tests of Hardy–Weinberg equilibrium (HWE) were conducted in controls stratified by self-identified race using Plink v1.05 [47]. In order to confirm that deviations from HWE were not due to erroneous genotype calls, genotyping cluster images were re-reviewed for SNPs with HWE P-values less than 0.01. SNPs reviewed during this process had acceptable signal intensity and cluster definitions, and none were excluded. Overall, 1373 of 1536 (89%) SNPs passed quality control, including 104 of 127 (82%) in ADIPOQ, LEP, and LEPR and 144 of 158 (91%) AIMs.
Subject data were excluded because of genotype calls for less than 95% of SNPs (N = 103), gender mismatch (N = 5), and suspected contamination (N = 1), yielding data for 1776 of 2022 (88%) controls and 1972 of 2311 (85%) cases (Table 1). Participants without genotype data were more likely to be cases, recruited in the second half of the study, and African American. 1220 of 2311 (53%) cases had both genotyping and tumor subtype data; missing genotype data were not associated with tumor subtype.
Table 1
Table 1
Characteristics of CBCS participants with genotyping data
Variables
Age was defined as age at breast cancer diagnosis for cases or age at study sampling for controls, and was included in models as a continuous variable. Self-identified race was white for 2293 participants, African American for 1400, and missing for 2. Less than 2% of participants reported that they were of another race, and were grouped with white women as non-African American.
Maximum likelihood methods were used to estimate individual proportions of African and European ancestry from 144 AIMs [48]. The median proportion of African ancestry was 81% among self-reported African Americans and 6% among self-reported non-African Americans. African ancestry was used in regression models as a proportion ranging from 0 to 0.96 (the maximum proportion African ancestry).
Body size was measured using standardized equipment [49]. WHR was the ratio of waist circumference to hip circumference, and was categorized based on the tertile distribution in controls. WHR associations with basal-like and luminal A breast cancer were similar for tertiles 2 and 3 (vs. tertile 1) [10], so those two categories were combined. Body mass index (BMI, weight in kg/height in m2), a potential confounder of WHR associations with breast cancer [50, 51], was included in regression models as a continuous variable. WHR and/or BMI information were missing for 50 cases and 40 controls.
Self-reported family history of breast cancer in a first degree relative was used as a binary variable (yes/no).
Statistical analysis
Allele frequencies were adjusted for the sampling probabilities used to sample participants (online resource 1). R2 was calculated in Haploview v3 [52]. Both were stratified by case status and self-identified race.
Odds ratios (ORs) and 95% confidence intervals (CIs) for genotype associations with breast cancer overall were estimated using unconditional binary logistic regression using SAS v9.1.3 (SAS, Cary, NC). Associations with basal-like and luminal A breast cancers were estimated using unconditional polytomous logistic regression and statistics testing the equality of parameter estimates for basal-like and luminal A subtypes were calculated based on the asymptotic chi-square distribution of the Wald statistic. Confidence limit ratios (CLRs, upper confidence limit divided by lower confidence limit) were calculated as a measure of relative precision [53]. As mentioned above, this analysis focused on basal-like and luminal A breast cancer; associations for other subtypes were not evaluated.
Genotype associations were modeled using the codominant model, as this does not assume a specific model form for the genotype effects and has greater power than other incorrectly specified model forms when the true underlying mode of inheritance is unknown [54]. If homozygote counts were less than 5 cases, less than 5 controls, or less than 10 cases and 10 controls, rare homozygote and heterozygote categories were combined. If results using the co-dominant model indicated that the underlying model may be recessive or dominant additional analyses specific to that model were conducted. Estimates for associations with basal-like breast cancer were expected to be less precise than associations for luminal A breast cancer due to the smaller number of basal-like cases. Therefore, the results presented were chosen based on both the strength of the OR and precision to avoid bias in reporting results by subtype. Associations with a relatively strong OR (OR ≥ 1.5 or OR ≤ 0.67) or a P-value < 0.05 and a precise CI (CLR ≤ 5) are reported in the results; sample size by genotype for these SNPs is given in online resource 2.
Models were adjusted initially for age and self-identified race, and an offset term was included in models to account for randomized recruitment sampling [37]. Confounding due to ancestry was assessed using the change-in-estimate approach, where a log OR change of 0.10 or more in either direction was considered a meaningful difference. Adjustment for ancestry changed log ORs by more than 0.10 for the association between a subset of SNPs and luminal A breast cancer, and so models were also adjusted for ancestry. Residual confounding by family history of breast cancer was assessed using the same approach. Additional adjustment for family history of breast cancer only affected the results for two SNPs (rs6413506 and rs4655555), and so family history was added to the final regression models for these SNPs only.
Log-additive model ORs and P-values were also calculated for SNP associations. Monte Carlo methods were used to approximate the joint distribution of test statistics and evaluate the family wise error rate to control for multiple comparisons [55]. Estimation of the joint distribution of test statistics before adjusting the alpha level insures that correlation among SNPs does not result in an overly conservative correction. The nominal alpha level for genotype associations was 0.05, and the Monte Carlo-adjusted alpha level was 0.001. All statistical tests were 2-sided.
To determine whether SNPs associated with breast cancer were associated with WHR, ORs for the association between breast cancer-associated SNPs and WHR were estimated using logistic regression in control subjects only, adjusting for BMI and the offset term.
Haplotype analyses were performed using Hapstat [56, 57], which simultaneously estimates the OR parameters and haplotype distribution for a given group of SNPs using maximum likelihood estimation and the EM algorithm. This approach yields unbiased estimates of ORs with appropriate variance estimates when haplotype phase is unknown. Modifications to Hapstat allowed for inclusion of an offset term and relaxation of the assumption of independence between genotypes and environmental variables [58].
For each gene, a 3-SNP sliding window was used to estimate a global P-value for the association between case status and all possible haplotypes in the window. Estimation of individual haplotype effects was pursued for haplotypes with a frequency ≥0.05 in controls (online resource 3) that were present in windows with the strongest global associations (P < 0.01); an a priori cut-point was not used. Regions were also selected by reviewing genotype ORs for consecutive strings of breast cancer-associated SNPs. Haplotype ORs and 95% CIs were estimated using the codominant model, and adjusted for age, self-identified race, ancestry, and the offset term. Haplotypes with a relatively strong OR (≥1.5 or ≤0.67) or a P < 0.05 and a precise CI (CLR ≤ 5) are reported in the results. Haplotype analyses were exploratory and predicated on SNP associations, and therefore were not adjusted for multiple comparisons.
Multiplicative genotype- and haplotype-WHR interaction was tested by evaluating the statistical significance of a multiplicative genotype- or haplotype-WHR interaction term. Literature reviews have shown that associations between WHR and premenopausal breast cancer were biased towards the null in studies that did not adjust for BMI [50, 51], and a similar pattern was observed in the CBCS for the association between WHR and breast cancer overall (data not shown). Therefore, BMI was included as a confounder in models evaluating WHR interaction. Directed acyclic graph analysis suggested that menopausal status, parity, and lactation were also potential confounders, but inclusion of these covariates did not change the WHR-breast cancer subtype log ORs by ≥ 0.10, and they were not included in final models. Genotype-WHR interaction was evaluated for all SNPs, and P-values were adjusted for multiple comparisons using Monte Carlo methods, described above. The nominal alpha level for interaction analyses was 0.10, and the Monte Carlo-adjusted alpha level was 0.002. Haplotype-WHR interaction was evaluated using an alpha level of 0.10.
Genotype associations
SNP associations with breast cancer overall were modest, with many effect estimates near the null (Table 2). When stratified by subtype, some ORs were suggestive of specific patterns: a group of 3 SNPs (rs17412175, rs9436746, and rs9436748) spanning 6786 base pairs in LEPR intron 2 were inversely associated with basal-like breast cancer, with ORs ranging from 0.48 to 0.57 (Table 2). The SNPs showed varying levels of moderate to low LD in controls (online resource 4). Subtype-specific associations were less consistent for ADIPOQ SNPs, some of which were inversely associated with the luminal A (rs16861194) and basal-like (rs16861205) subtypes, and for LEP SNPs, some of which were positively associated with luminal A (rs6976701, rs17151922) and basal-like (rs10954174) subtypes (Table 2).
Table 2
Table 2
Association between selected SNPsa in ADIPOQ, LEP, and LEPR and breast cancer in the CBCS
Candidate SNPs LEPR K109R (rs1137100) and Q223R (rs1137101) were positively associated with luminal A breast cancer but not basal-like breast cancer, though associations were not statistically different between the two subtypes (Table 2). In addition, K109R and LEPR K656N (rs8179183) were associated with breast cancer overall (Table 2). ADIPOQ SNPs +45 T/G (rs2241766) and +276 G/T (rs1501299) were not associated with breast cancer overall or by subtype (online resource 5).
Of the SNPs in Table 2, ADIPOQ rs16861194 and LEPR rs12042877 were associated with WHR, though neither was in the direction expected based on the breast cancer risk allele (online resource 6). No tag or candidate SNP associations with breast cancer were statistically significant after accounting for multiple comparisons.
Haplotype associations
Haplotypes in LEP (haplotypes 1, 2a, 2b, 3) and LEPR (haplotype 6b) were strongly associated with breast cancer overall or luminal A breast cancer, with ORs of 2 or greater (Table 3). LEP haplotype 3 and LEPR haplotype 4a were associated with basal-like breast cancer with moderate precision (Table 3); haplotype 4a includes rs17412175, rs9436746, and rs9436748, which were each individually associated with basal-like breast cancer.
Table 3
Table 3
Association between selected haplotypes and breast cancer in the CBCS
Overall, haplotype associations were stronger than individual SNP associations: the strongest haplotype association was between haplotype 3 and luminal A breast cancer (OR = 3.21, Table 3), whereas the strongest SNP association was an OR of 0.48 (rs9436748 and basal-like breast cancer, Table 2).
Interaction with WHR
Tests of multiplicative interaction between SNPs and WHR were not significant after adjustment for multiple comparisons. In addition, there was no evidence of haplotype interaction with WHR.
We estimated associations between tag and candidate SNPs in ADIPOQ, LEP, and LEPR and basal-like breast cancer, luminal A breast cancer, and breast cancer overall in a population-based study of white and African American women. With respect to tag SNPs, our main finding was that three LEPR SNPs (rs17412175, rs9436746, rs9436748) in close proximity were inversely associated with basal-like breast cancer; associations between these SNPs and luminal A breast cancer were weak. The SNPs are in moderate to weak LD in cases and controls, and may be markers of a single genetic factor. Other SNP associations showed few discernible patterns: SNPs in a particular gene were not associated only with the basal-like subtype or only with the luminal A subtype. It is likely that many of these associations represent false-positive results. As such, replication in an independent dataset is necessary before further conclusions can be made.
Candidate SNPs in LEPR, but not ADIPOQ, were associated with luminal A breast cancer and/or breast cancer overall (Table 2). LEPR Q223R (rs1137101) was positively associated with luminal A breast cancer in the CBCS; however, the association was not as strong as that reported by Snoussi et al. [27] (online resource 5). Q223R associations with breast cancer have been inconsistent, and reported as both inverse [21, 28] and null [25, 29]; another study suggested that there was a positive association with breast cancer limited to premenopausal women [30]. Quinton et al. [59] reported that the 223R variant was associated with increased serum leptin levels, which is consistent with the hypothesis that altered serum adipocytokine levels are part of the mechanism linking genetic variation to breast cancer risk. Given that Q223R was associated only with luminal A breast cancer and not breast cancer overall in our study, it is possible that some of the variation in results seen in other studies is due to tumor heterogeneity and, more specifically, the relative proportion of luminal A breast cancers in each population.
LEPR K109R (rs1137100) was positively associated with breast cancer overall and the luminal A subtype in the CBCS, in contrast to two previously reported null associations [28, 29]. Reports vary on the biological effect of LEPR K109R on serum leptin levels in women. Two studies reported that healthy women with codon 109 RR variants had higher serum leptin levels compared to women with 109 QR variants [28, 60]. In contrast, another study reported that leptin levels were lower among postmenopausal women with at least one copy of the 109R variant, and that there was no association among premenopausal women [61], and two other studies reported no association [62, 63]. A limitation of our study was that adipocytokine levels were not measured. Thus, although we observed associations between Q223R, K109R, and K656N and breast cancer, we were unable to determine whether these SNPs were also associated with changes in adipocytokine levels in our population. Analysis of such intermediate markers can provide support for a hypothesized mechanism, and may provide biological evidence to support genotype associations in future studies.
The molecular mechanisms by which K109R, K656N, or Q223R might affect the leptin receptor have not been identified. A series of experiments showed that the Q223R polymorphism did not affect transcription in mouse models or leptin receptor activity in vitro [64], which conflicts with previously reported associations between Q223R and circulating leptin levels [59, 65, 66]. Further research is necessary to confirm whether these candidate SNPs have functional effects or are markers for other causal genetic variants.
Previously investigated candidate SNPs were not associated with basal-like breast cancer in the CBCS. This may be due to greater imprecision for basal-like estimates because of the smaller number of cases. Another potential explanation is that the candidate SNPs examined in previous studies were examined in all breast cancer cases grouped together, the majority of which are likely to be luminal A breast cancers. It is possible that different functional variants are associated with basal-like tumors. Low penetrance variants specific to the basal-like subtype are unlikely to be detected if basal-like cases constitute a minority of the overall case group.
We used both agnostic (sliding window) and informed (based on SNP ORs) approaches to identify haplotype effects, and found the two approaches to be complementary. Haplotype associations were generally in the same direction as genotype associations for the involved SNPs, and in many cases, the magnitude of the haplotype OR exceeded that of any single SNP within the haplotype. Notably, in the case of LEP haplotype 1 the individual genotypes showed no association with breast cancer overall or by subtype (online resource 7), but the haplotype analysis revealed a strong association when the alleles were evaluated jointly. Conversely, many of the breast cancer-associated haplotypes identified by evaluating SNPs with strong genotype associations were not identified by the sliding window analysis. This is likely because the sliding window analysis estimated a global test statistic for all possible haplotypes within the SNP window. Such an analysis may have low power if the majority of haplotypes are not associated with the outcome.
There was potential for selection bias to influence study results, since genotyping data were more likely to be missing for cases and African Americans. Adjustment for self-identified race and age should control for this possible selection bias, assuming that there was no additional bias within case, race, and age strata [67]. Selection bias may have also occurred when determining the breast cancer subtype, as sufficient immunohistochemistry was not available for 47% of enrolled cases. However, genotype distributions between cases with and without subtype information were similar, as was the molecular subtype distribution comparing cases with and without genotyping data (data not shown). This suggests that the genotype distribution in the subset of cases with tumor subtype information was likely representative of the genotype distribution in all cases.
Strengths of this study include analysis of a comprehensive set of tag SNPs enriched with candidate SNPs to increase the chances of detecting a genomic region associated with breast cancer. Tag SNPs were chosen from European and African populations to account for different LD patterns among participants of African or European ancestry, and all associations were adjusted for individual proportions of African ancestry, minimizing residual con-founding due to population stratification within self-identified race groups. Although estimates for the basal-like subtype were less precise compared to the luminal A estimates due to smaller sample size, the results presented were chosen based on both OR magnitude and precision to avoid reporting bias that would have resulted from using statistical significance as the sole criteria for evaluating results by subtype.
In summary, the consistency of the strength and direction of association with basal-like breast cancer points toward the 3-SNP region in LEPR intron 2 as a promising candidate for an association with basal-like breast cancer risk. Furthermore, LEPR candidate SNPs K109R and Q223R were associated with luminal A breast cancer and breast cancer overall. These results suggest that genetic variation in LEPR may be associated with breast cancer risk, but that specific regions may have subtype-specific effects.
Supplementary Material
Supplementary
Acknowledgments
The authors wish to thank Patricia Basta, Michael Andre, and Amanda Beaty for their work in preparing the DNA samples and conducting the genotyping. The authors also thank Jessica Tse for advice and statistical support. Sarah J. Nyante was supported by the Lineberger Cancer Center Cancer Control Education Program Predoctoral Fellowship (R25 CA57726). The Carolina Breast Cancer Study was funded by the Specialized Program of Research Excellence (SPORE) in Breast Cancer at UNC (NIH/NCI P50-CA58223) and the Lineberger Comprehensive Cancer Center Core Grant (P30-CA16086).
Footnotes
Electronic supplementary material The online version of this article (doi:10.1007/s10549-011-1517-z) contains supplementary material, which is available to authorized users.
Contributor Information
Sarah J. Nyante, Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Marilie D. Gammon, Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Jay S. Kaufman, Department of Epidemiology, Biostatistics, & Occupational Health, McGill University, Montreal, QC, Canada.
Jeannette T. Bensen, Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Dan Yu Lin, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA, Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA.
Jill S. Barnholtz-Sloan, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Yijuan Hu, Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA.
Qianchuan He, Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA.
Jingchun Luo, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Robert C. Millikan, Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
1. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, Hanby A. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22–34. [PubMed]
2. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264–271. [PubMed]
3. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37(9):1217–1226. [PubMed]
4. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006;12(5):1533–1539. [PubMed]
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295(21):2492–2502. [PubMed]
6. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M, Nakashima K. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast. 2007;16(Suppl 2):S72–S77. [PubMed]
7. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA. Germline brca1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482–1485. [PubMed]
8. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, et al. Prediction of brca1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11(14):5175–5180. [PubMed]
9. Turner NC, Reis-Filho JS. Basal-like breast cancer and the brca1 phenotype. Oncogene. 2006;25(43):5846–5853. [PubMed]
10. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123–139. [PMC free article] [PubMed]
11. Schaffler A, Scholmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab. 2007;3(4):345–354. [PubMed]
12. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5(3):153–165. [PubMed]
13. Fredriksson J, Carlsson E, Orho-Melander M, Groop L, Ridderstrale M. A polymorphism in the adiponectin gene influences adiponectin expression levels in visceral fat in obese subjects. Int J Obes (Lond) 2006;30(2):226–232. [PubMed]
14. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007;8(5):395–408. [PubMed]
15. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94(9):1221–1225. [PMC free article] [PubMed]
16. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89(3):1102–1107. [PubMed]
17. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, Chen HY, Hou MF, Yuan SS. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237(1):109–114. [PubMed]
18. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, Mantzoros CS. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2007;92(3):1041–1048. [PubMed]
19. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9(15):5699–5704. [PubMed]
20. Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci. 2007;22(1):117–121. [PMC free article] [PubMed]
21. Han CZ, Du LL, Jing JX, Zhao XW, Tian FG, Shi J, Tian BG, Liu XY, Zhang LJ. Associations among lipids, leptin, and leptin receptor gene gin223arg polymorphisms and breast cancer in china. Biol Trace Elem Res. 2008;126(1–3):38–48. [PubMed]
22. Mantzoros CS, Bolhke K, Moschos S, Cramer DW. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer. 1999;80(4):523–526. [PubMed]
23. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D. Leptin and insulin growth factor i in relation to breast cancer (greece) Cancer Causes Control. 2000;11(5):383–388. [PubMed]
24. Stattin P, Soderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, Olsson T. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat. 2004;86(3):191–196. [PubMed]
25. Cleveland RJ, Gammon MD, Long CM, Gaudet MM, Eng SM, Teitelbaum SL, Neugut AI, Santella RM. Common genetic variations in the lep and lepr genes, obesity and breast cancer incidence and survival. Breast Cancer Res Treat. 2010;120(3):745–752. doi:10.1007/s10549-009-0503-1. [PMC free article] [PubMed]
26. Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, Ahsan H, Pasche B, Mantzoros C. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res. 2008;68(9):3178–3184. [PMC free article] [PubMed]
27. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Helal AN, Chouchane L. Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer. 2006;6:38. [PMC free article] [PubMed]
28. Woo HY, Park H, Ki CS, Park YL, Bae WG. Relationships among serum leptin, leptin receptor gene polymorphisms, and breast cancer in Korea. Cancer Lett. 2006;237(1):137–142. [PubMed]
29. Teras LR, Goodman M, Patel AV, Bouzyk M, Tang W, Diver WR, Feigelson HS. No association between polymorphisms in lep, lepr, adipoq, adipor1, or adipor2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2553–2557. doi:10.1158/1055-9965.EPI-09-0542. [PubMed]
30. Okobia MN, Bunker CH, Garte SJ, Zmuda JM, Ezeome ER, Anyanwu SN, Uche EE, Kuller LH, Ferrell RE, Taioli E. Leptin receptor gln223arg polymorphism and breast cancer risk in Nigerian women: a case control study. BMC Cancer. 2008;8:338. [PMC free article] [PubMed]
31. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007;16(3):439–443. [PubMed]
32. Kristensen VN, Borresen-Dale AL. Snps associated with molecular subtypes of breast cancer: on the usefulness of stratified genome-wide association studies (gwas) in the identification of novel susceptibility loci. Mol Oncol. 2008;2(1):12–15. [PubMed]
33. Nordgard SH, Johansen FE, Alnaes GI, Naume B, Borresen-Dale AL, Kristensen VN. Genes harbouring susceptibility snps are differentially expressed in the breast cancer subtypes. Breast Cancer Res. 2007;9(6):113. [PMC free article] [PubMed]
34. Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of b-myb in basal-like breast cancer. Oncogene. 2009;28(5):742–751. [PMC free article] [PubMed]
35. Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, Liu ET. The Carolina breast cancer study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat. 1995;35(1):51–60. [PubMed]
36. Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, Huang WY, Geradts J, Iacocca M, Cowan D, Conway K, Dressler L. Her2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat. 2003;79(3):355–364. [PubMed]
37. Weinberg CR, Sandler DP. Randomized recruitment in case-control studies. Am J Epidemiol. 1991;134(4):421–432. [PubMed]
38. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000;151(7):703–714. [PubMed]
39. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, et al. Immuno-histochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–5374. [PubMed]
40. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007;38(2):197–204. [PubMed]
41. de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet. 2005;37(11):1217–1223. [PubMed]
42. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004;74(1):106–120. [PubMed]
43. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, et al. A second generation human haplotype map of over 3.1 million snps. Nature. 2007;449(7164):851–861. [PMC free article] [PubMed]
44. Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, Brennan DJ, Millikan RC. Fgfr2 and other loci identified in genome-wide association studies are associated with breast cancer in african-american and younger women. Carcinogenesis. 2010;31(8):1417–1423. doi:10.1093/carcin/bgq128. [PMC free article] [PubMed]
45. Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, Seldin MF. A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. Am J Hum Genet. 2006;79(4):640–649. [PubMed]
46. Barnholtz-Sloan JS, McEvoy B, Shriver MD, Rebbeck TR. Ancestry estimation and correction for population stratification in molecular epidemiologic association studies. Cancer Epidemiol Biomarkers Prev. 2008;17(3):471–477. [PubMed]
47. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet. 2005;76(5):887–893. [PubMed]
48. Barnholtz-Sloan JS, Chakraborty R, Sellers TA, Schwartz AG. Examining population stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol Biomarkers Prev. 2005;14(6):1545–1551. [PubMed]
49. Hall IJ, Newman B, Millikan RC, Moorman PG. Body size and breast cancer risk in black women and white women: the carolina breast cancer study. Am J Epidemiol. 2000;151(8):754–764. [PubMed]
50. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003;4(3):157–173. [PubMed]
51. Connolly BS, Barnett C, Vogt KN, Li T, Stone J, Boyd NF. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer. 2002;44(2):127–138. [PubMed]
52. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of ld and haplotype maps. Bioinformatics. 2005;21(2):263–265. [PubMed]
53. Poole C. Low P-values or narrow confidence intervals: which are more durable? Epidemiology. 2001;12(3):291–294. [PubMed]
54. Lettre G, Lange C, Hirschhorn JN. Genetic model testing and statistical power in population-based association studies of quantitative traits. Genet Epidemiol. 2007;31(4):358–362. [PubMed]
55. Lin DY. An efficient Monte Carlo approach to assessing statistical significance in genomic studies. Bioinformatics. 2005;21(6):781–787. doi:10.1093/bioinformatics/bti053. [PubMed]
56. Lin DY, Zeng D, Millikan R. Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol. 2005;29(4):299–312. [PubMed]
57. Lin DY, Zeng D. Likelihood-based inference on haplotype effects in genetic association studies. J Am Stat Assoc. 2006;101(473):89–118.
58. Hu YJ, Lin DY, Zeng D. A general framework for studying genetic effects and gene–environment interactions with missing data. Biostatistics. 2010;11(4):583–598. doi:10.1093/biostatistics/kxq 015. [PMC free article] [PubMed]
59. Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI. A single nucleotide polymorphism (snp) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet. 2001;108(3):233–236. [PubMed]
60. van Rossum CT, Hoebee B, van Baak MA, Mars M, Saris WH, Seidell JC. Genetic variation in the leptin receptor gene, leptin, and weight gain in young Dutch adults. Obes Res. 2003;11(3):377–386. [PubMed]
61. Wauters M, Mertens I, Chagnon M, Rankinen T, Considine RV, Chagnon YC, Van Gaal LF, Bouchard C. Polymorphisms in the leptin receptor gene, body composition and fat distribution in overweight and obese women. Int J Obes Relat Metab Disord. 2001;25(5):714–720. [PubMed]
62. Kim SM, Kim SH, Lee JR, Jee BC, Ku SY, Suh CS, Choi YM, Kim JG, Moon SY. Association of leptin receptor polymorphisms lys109arg and gln223arg with serum leptin profile and bone mineral density in Korean women. Am J Obstet Gynecol. 2008;198(4):e421–e428. doi:10.1016/j.ajog.2007.10.799. [PubMed]
63. Ogawa T, Hirose H, Yamamoto Y, Nishikai K, Miyashita K, Nakamura H, Saito I, Saruta T. Relationships between serum soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile, and leptin receptor gene polymorphisms in the Japanese population. Metabolism. 2004;53(7):879–885. [PubMed]
64. Stratigopoulos G, Le Duc CA, Matsuoka N, Gutman R, Rausch R, Robertson SA, Myers MG, Jr, Chung WK, Chua SC, Jr, Leibel RL. Functional consequences of the human leptin receptor (lepr) q223r transversion. Obesity (Silver Spring) 2009;17(1):126–135. [PMC free article] [PubMed]
65. Ragin CC, Dallal C, Okobia M, Modugno F, Chen J, Garte S, Taioli E. Leptin levels and leptin receptor polymorphism frequency in healthy populations. Infect Agent Cancer. 2009;4(Suppl 1):13. doi:10.1186/1750-9378-4-S1-S13. [PMC free article] [PubMed]
66. Ali Ben S, Kallel A, Sediri Y, Ftouhi B, Feki M, Slimene H, Jemaa R, Kaabachi N. Lepr p.Q223r polymorphism influences plasma leptin levels and body mass index in Tunisian obese patients. Arch Med Res. 2009;40(3):186–190. doi:10.1016/j.arcmed.2009.02.008. [PubMed]
67. Savitz DA. Interpreting epidemiologic evidence. Oxford University Press; New York: 2003.